LRIG2 promotes glioblastoma progression by modulating innate antitumor immunity through macrophage infiltration and polarization
JOURNAL FOR IMMUNOTHERAPY OF CANCER(2022)
Abstract
Background Glioblastoma (GBM) is the most common malignant brain tumor with poor clinical outcomes. Immunotherapy has recently been an attractive and promising treatment of extracranial malignancies, however, most of clinical trials for GBM immunotherapy failed due to predominant accumulation of tumor-associated microglia/macrophages (TAMs). Results High level of LRIG2/soluble LRIG2 (sLRIG2) expression activates immune-related signaling pathways, which are associated with poor prognosis in GBM patients. LRIG2/sLRIGs promotes CD47 expression and facilitates TAM recruitment. Blockade of CD47-SIRP alpha interactions and inhibition of sLRIG2 secretion synergistically suppress GBM progression in an orthotropic murine GBM model. Conclusions GBM cells with high level LRIG2 escape the phagocytosis by TAM via the CD47-SIRP alpha axis, highlighting a necessity for an early stage of clinical trial targeting LRIG2 and CD47-SIRP alpha as a novel treatment for patients with GBM.
MoreTranslated text
Key words
Phagocytosis,Brain Neoplasms,Tumor Microenvironment,Macrophages
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined